Biopharmaceutical corporation H. Lundbeck invested an undisclosed amount in Ossianix, a US-based biopharmaceutical company specialising in the treatment of nervous system disorders, on Tuesday.
The funding will be used to develop Ossianix’s antibody treatment platform, which it hopes will form the basis of a range of products and technologies, for which Lundbeck will retain the right to negotiate.
Peter Høngaard Andersen, senior vice president, External Scientific Relations at Lundbeck, said: "We at Lundbeck look forward to following the development of Ossianix’s exciting new technology. We wish to develop our biologics portfolio further and Ossianix’s technology has the potential to tailor the power of the single domain antibodies to a variety of unique drug targets."
Frank S. Walsh, chief executive officer of Ossianix, added: "Lundbeck is a recognized leader in producing drugs for neurological and psychiatric disorders. We are very pleased that Lundbeck, via this investment, has chosen to further extend their involvement in the emerging field of biotherapeutics for [central nervous system] disorders."
The investment follows Lundbeck’s signing of a strategic partnership with another nervous system specialist, the Proximagen Group, in September.